Optimization of Circulating Biomarkers of Obatoclax-Induced Cell Death in Patients with Small Cell Lung Cancer

Por Dean, Emma J, Cummings, Jeff, Roulston, Anne, Berger, Mark, Ranson, Malcolm, Blackhall, Fiona, Dive, Caroline
Publicado em 2011

DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer

Por Board, Ruth E, Knight, Lucy, Greystoke, Alastair, Blackhall, Fiona H, Hughes, Andrew, Dive, Caroline, Ranson, Malcolm
Publicado em 2008

Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer

Por Hou, Jian-Mei, Krebs, Matthew, Ward, Tim, Sloane, Robert, Priest, Lynsey, Hughes, Andrew, Clack, Glen, Ranson, Malcolm, Blackhall, Fiona, Dive, Caroline
Publicado em 2011

Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy

Por Hou, Jian-Mei, Greystoke, Alastair, Lancashire, Lee, Cummings, Jeff, Ward, Tim, Board, Ruth, Amir, Eitan, Hughes, Sarah, Krebs, Matthew, Hughes, Andrew, Ranson, Malcolm, Lorigan, Paul, Dive, Caroline, Blackhall, Fiona H.
Publicado em 2009

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients

Por Saleem, Azeem, Matthews, Julian C., Ranson, Malcolm, Callies, Sophie, André, Valérie, Lahn, Michael, Dickinson, Claire, Prenant, Christian, Brown, Gavin, McMahon, Adam, Talbot, Denis C., Jones, Terry, Price, Patricia M.
Publicado em 2011

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours

Por Evans, T. R. Jeffry, Dean, Emma, Molife, L. Rhoda, Lopez, Juanita, Ranson, Malcolm, El-Khouly, Fatima, Zubairi, Ishtiaq, Savulsky, Claudio, Reyderman, Larisa, Jia, Yan, Sweeting, Lorna, Greystoke, Alastair, Barriuso, Jorge, Kristeleit, Rebecca
Publicado no Br J Cancer (2019)

First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014

Por Basu, Bristi, Dean, Emma, Puglisi, Martina, Greystoke, Alastair, Ong, Michael, Burke, Wendy, Cavallin, Maria, Bigley, Graham, Womack, Christopher, Harrington, Elizabeth A, Green, Stephen, Oelmann, Elisabeth, de Bono, Johann S, Ranson, Malcolm, Banerji, Udai
Publicado no Clin Cancer Res (2015)

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

Por Rodon, Jordi, PérezFidalgo, Alejandro, Krop, Ian E., Burris, Howard, Guerrero-Zotano, Angel, Britten, Carolyn D., Becerra, Carlos, Schellens, Jan, Richards, Donald A., Schuler, Martin, Abu-Khalaf, Maysa, Johnson, Faye M., Ranson, Malcolm, Edenfield, Jeff, Silva, Antonio P., Hackl, Wolfgang, Quadt, Cornelia, Demanse, David, Duval, Vincent, Baselga, Jose
Publicado no Cancer Chemother Pharmacol (2018)

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Por Rudin, Charles M., Hann, Christine L., Garon, Edward B., Ribeiro de Oliveira, Moacyr, Bonomi, Philip D., Camidge, D. Ross, Chu, Quincy, Giaccone, Giuseppe, Khaira, Divis, Ramalingam, Suresh S., Ranson, Malcolm R., Dive, Caroline, McKeegan, Evelyn M., Chyla, Brenda J., Dowell, Barry L., Chakravartty, Arunava, Nolan, Cathy E., Rudersdorf, Niki, Busman, Todd A., Mabry, Mack H., Krivoshik, Andrew P., Humerickhouse, Rod A., Shapiro, Geoffrey I., Gandhi, Leena
Publicado em 2012

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Por Cross, Darren A. E., Ashton, Susan E., Ghiorghiu, Serban, Eberlein, Cath, Nebhan, Caroline A., Spitzler, Paula J., Orme, Jonathon P., Finlay, M. Raymond V., Ward, Richard A., Mellor, Martine J., Hughes, Gareth, Rahi, Amar, Jacobs, Vivien N., Brewer, Monica Red, Ichihara, Eiki, Sun, Jing, Jin, Hailing, Ballard, Peter, Al-Kadhimi, Katherine, Rowlinson, Rachel, Klinowska, Teresa, Richmond, Graham H. P., Cantarini, Mireille, Kim, Dong-Wan, Ranson, Malcolm R., Pao, William
Publicado no Cancer Discov (2014)